Jeremy Levin, Ovid CEO (BIO via YouTube)
July 9, 2021 07:10 AM EDTUpdated 04:38 PM
People
R&D
Pharma

Ovid shuf­fles C-suite, lays off staff in wake of PhI­II An­gel­man syn­drome fail

Max Gelman

Senior Editor

Fol­low­ing a Phase III flop and a culling of its pipeline, Ovid Ther­a­peu­tics is shak­ing things up again — this time at the C-suite lev­el. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

A service from the Financial Times